Proactive Investors - Run By Investors For Investors

Aphria rises after completing acquisition of German medical cannabis distributor

The Ontario company paid €18.92 million (US$22 million) in cash and with a possible earn-out multiple on future Ebitda of as much as another €23.5 million (US$27 million)
A photo indicating medical cannabis
CC Pharma operates a production, repackaging and labeling facility at its headquarters in Densborn, Germany

Aphria Inc (NYSE:APHA) rose Wednesday after announcing that it has completed its acquisition of CC Pharma GmbH, a distributor of drug products including medical cannabis to more than 13,000 pharmacies in Germany and throughout Europe.

Leamington, Ontario-based paid Aphria paid €18.92 million (US$22 million) in cash to the former shareholders of CC Pharma with an earn-out multiple on future earnings before interest, taxes, depreciation and amortization of as much as another €23.5 million (US$27 million) if certain milestones are met.

READ: Aphria's Colombian subsidiary Colcanna partners with Colombian medical federation

Shares of Aphria advanced $0.16, or 2.5%, to US$6.49 in New York’s premarket trading.

“As one of the most promising medical cannabis markets in the world, Germany is a top strategic priority for Aphria,” Vic Neufeld, CEO of Aphria, said in a press release. “With today’s acquisition of CC Pharma, Aphria is creating a German and ultimately pan-European platform that brings together demand, supply and distribution.” 

Founded in 1999, CC Pharma has more than 230 employees and offices in Germany, Denmark, Poland and the Czech Republic. The company holds 318 active German and 692 active European Union pharmaceutical licenses, Aphria said in a press release.

CC Pharma operates a production, repackaging and labeling facility at its headquarters in Densborn, Germany. In 2018, the company generated revenue of about €262 million (US$300 million), with Ebitda of about €10.5 million (US$12 million). 

Aphria is also active in South America. Earlier this month, it announced that its Colombian subsidiary, Colcanna SAS, is partnering with the Colombian Medical Federation, which oversees the ethics of the medical profession, to develop an academic curriculum on the medicinal use of cannabis.

Contact Dennis Fitzgerald at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full APH profile View Profile

Aphria Timeline

Related Articles

cannabis plan in sun
February 21 2019
The cannabis company will manufacture, infuse and package branded recreational and wellness products
medical cannabis concept
February 10 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use